Women using estrogen-only menopausal hormone therapy face a significantly lower risk of developing Alzheimer’s disease and associated brain pathology, according to a large Stanford Medicine study published August 12, 2026, in Neurology, challenging long-held assumptions about hormone treatments and cognitive health.
Stanford Study Analyzes Decades of Brain Autopsies and Clinical Records
The investigation included post-mortem examinations from nearly 3,000 brains donated to science, allowing investigators to look directly at the physical hallmarks of cognitive decline.
Rather than relying solely on clinical diagnoses, which can be complicated by overlapping memory conditions, the research team targeted the physical damage inside brain tissue. Investigators specifically checked for amyloid plaques and neurofibrillary tangles of tau protein, which disrupt communication between cells and cause cellular death.
“Our study is unique in that we looked at all the standards of Alzheimer’s diagnosis, including the gold-standard outcome: Alzheimer’s-associated hallmarks in autopsied brains. Many conditions impact memory. Clinical diagnoses are often not accurate… By looking where the actual damage is done – the brain – you can see where the Alzheimer’s-associated defining features are and how many of them are there.”
Dr. Hadi Hosseini, an associate professor of psychiatry and behavioral sciences at Stanford
When comparing brain autopsies from 258 women who reported estrogen-only menopausal hormone therapy with roughly 2,701 women who never used the treatment, the patterns were distinct. Patients using estrogen-only regimens exhibited a 35% lower chance of showing biological signs of Alzheimer’s disease. Clinical data across the broader participant pool similarly revealed a 39% lower odds of receiving a dementia diagnosis over a lifetime.
Biological Mechanisms and the Hysterectomy Factor
The observed reduction in disease pathology aligns closely with what scientists understand about estrogen’s biological footprint in the central nervous system. The hormone supports synaptic health and limits inflammatory responses within neural tissue.
“Estrogen has well-described neuroprotective effects in animal models,”
Jennifer Bruno, PhD, an instructor in psychiatry and behavioral sciences
“Estrogen plays a role in shifting amyloid toward the non-amyloidogenic pathway and promoting tau dephosphorylation — both amyloid and tau are hallmarks of Alzheimer’s disease.”
Photo: Thepharmacist
Jennifer Bruno, PhD, an instructor in psychiatry and behavioral sciences
These protective advantages apply specifically to estrogen-only hormone therapy, a prescription primarily recommended for patients who have undergone a hysterectomy. Because administering estrogen by itself thickens the uterine lining and elevates endometrial cancer risks, women retaining a uterus typically take progesterone alongside estrogen. The study’s authors noted that insufficient data prevented them from drawing conclusions regarding combination estrogen-plus-progestin formulations.
This distinction carries direct relevance for a substantial portion of the population. By age 60, more than 30% of women have had hysterectomies, meaning the potential brain health implications of estrogen-only regimens directly affect roughly one-third of individuals reaching menopausal age.
Reversing Decades of Medical Caution and Past Studies
The new findings stand in stark opposition to a generation of medical guidance shaped by early 2000s research. A major 2003 analysis known as the Women’s Health Initiative Memory Study linked hormone therapies—particularly combination regimens started later in life—to increased risks of dementia, cardiovascular disease, and breast cancer.
Photo: Stanford
Publicity surrounding those historical trials caused prescription rates to plummet.
Yet researchers point out that the participants in the Stanford investigation averaged 70 years of age, meaning they generally initiated treatment later in life than modern guidelines suggest. Emerging medical literature indicates that hormone therapy yields optimal protective benefits when initiated during or immediately following the onset of menopause.
“For a long time, the going recommendation was Don’t use MHT for memory decline. This study flies in the face of that recommendation.”
Despite the robust sample sizes and inclusion of biomarkers from blood and cerebrospinal fluid, experts emphasize that the observational design establishes correlation rather than direct causation. Unmeasured variables, such as baseline health habits or varying healthcare access among hormone users, could influence long-term outcomes.
Photo: New York Post
Independent organizations monitoring neurological health underscore that the findings should prompt further scientific inquiry rather than immediate lifestyle changes. Dr. Tom Blackmore, research programmes manager at Alzheimer’s Research UK, noted that women receiving hormone therapy may differ from non-users in ways that independently support long-term brain health.
Study authors agree that randomized controlled trials remain necessary to confirm whether the observed association translates into a clinically proven preventive tool against cognitive decline.
